PERISINK ? Control of the Peripheral sink and thus serum half-life of biologics via harnessing glycan-specific internalisation

Forschungsstelle

INNOSUISSE

Projektnummer

132.767 IP-LS

Projekttitel

PERISINK ? Control of the Peripheral sink and thus serum half-life of biologics via harnessing glycan-specific internalisation

Projekttitel Englisch

PERISINK ? Control of the Peripheral sink and thus serum half-life of biologics via harnessing glycan-specific internalisation

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Schlüsselwörter	-	-	-
Abstract	-	-	-

Kategorie	Text
Schlüsselwörter (Englisch)	Life sciences, Biotechnology and processing
Abstract (Englisch)	InCephalo is a preclinical-stage biotech company developing innovative therapies for CNS diseases. This project focuses on advancing the C-Lock platform by developing glycan-optimized variants of biologics, enabling tunable systemic half-life without compromising activity.